Compare PTGX & NCLH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTGX | NCLH |
|---|---|---|
| Founded | 2006 | 1966 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 8.9B |
| IPO Year | 2016 | 2011 |
| Metric | PTGX | NCLH |
|---|---|---|
| Price | $138.00 | $20.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 17 |
| Target Price | ★ $108.23 | $24.76 |
| AVG Volume (30 Days) | 593.6K | ★ 14.4M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.05 | ★ 0.71 |
| Revenue | N/A | ★ $5,396,175,000.00 |
| Revenue This Year | $874.25 | $9.96 |
| Revenue Next Year | N/A | $6.60 |
| P/E Ratio | $2,645.60 | ★ $85.91 |
| Revenue Growth | N/A | ★ 10.71 |
| 52 Week Low | $50.49 | $14.53 |
| 52 Week High | $143.29 | $27.18 |
| Indicator | PTGX | NCLH |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 75,000). It operates 35 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 16 passenger vessels on order among its brands through 2037, representing 43,000 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.